fda warning bpc-157 not approved safety concerns The peptide problem: Hype is outrunning the evidence The FDA is reviewing which

The research team of Frias et al designed a 32-week, randomized, double-blind, parallel-group, active control trial that included adults with a diagnosis of type 2 diabetes and a body mass index of 27 and HbA1C levels ranging from 7.5% to 10% despite a daily dose of metformin

Therapeutically, the synthetically produced peptide BPC-157 is not currently approved for use as a human drug

Reported side effects in available research and clinical use include fatigue, headaches, nausea, and injection site irritation generally mild, but again, incompletely characterized over long-term use

Peripheral blood smear revealed anemia with anisopoikilocytosis and 1-2+ schistocytes, as well as thrombocytopenia without satellitosis or aggregation

This rapid dumping of poisons can make you feel sick and achy